NEW YORK, Oct. 9, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Atossa Genetics, Inc. ("Atossa" or the "Company") (NASDAQ: ATOS), concerning whether the board has breached its fiduciary duties to shareholders.
On October 4, 2013, Atossa disclosed that it would be forced to recall its ForeCYTE Breast Health Test and Mammary Aspiration Specimen Cytology Test. The recall was necessary to address concerns raised by the FDA. The FDA previously alerted the Company to concerns regarding the recalled products. Those concerns may not have been addressed by Atossa.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Atossa shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP